Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mayumi Jijiwa has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Integrated Plasma snoRNA–Protein Network Analysis Identifies Circulating Molecular Signatures Associated with High-Risk Benign Breast Lesions and Early Breast Cancer

    by Mayumi Jijiwa, Vedbar S. Khadka, Matthew Huo, Lauren Higa, Shaina Young, Youping Deng

    High-risk benign breast lesions increase subsequent breast cancer risk, yet circulating molecular patterns that distinguish them from early breast cancer remain poorly defined. We profiled plasma small nucleolar RNAs (snoRNAs) and small Cajal body-specific RNAs (scaRNAs) using UMI-based small RNA sequencing in 32 plasma samples from patients with low-risk benign lesions (Be; 9), high-risk benign lesions (HB; 14), or early breast cancer (CA; 9), and integrated matched data-independent acquisition (DIA) proteomics in a subset of 20 samples (HB; 11, CA; 9). Weighted gene co-expression network analysis (WGCNA) of 475 molecular features identified 11 modules. The Yellow module contained 25 snoRNAs/scaRNAs and 26 proteins and was enriched for extracellular matrix (ECM), blood microparticle, platelet, and serine-type endopeptidase inhibitor functions. An exploratory Yellow-module-focused analysis identified 10 snoRNAs with nominally lower abundance in CA than in HB (p < 0.05), showing concordant directions of differential abundance with the global analysis. The strength of differential RNA evidence correlated with mean intramodular RNA–protein correlation (Spearman ρ = 0.788, p = 2.85 × 10−6). External snoDB target mapping supported 28.6% of the exploratory network edges, including SNORD38A–FN1, SNORA73B–LAMB1, SNORD22–LAMB1, and SNORD22–NCAM1. Integration of differential plasma snoRNA profiling, cross-omic network analysis, and experimentally observed snoRNA interaction data indicated convergence on ECM/collagen and platelet/coagulation biology. These candidate snoRNA–protein axes may characterize differences in the circulating molecular states of CA and HB.

  • Open Access

    Subverting the Canon: Novel Cancer-Promoting Functions and Mechanisms for snoRNAs

    by Matthew Huo, Sudhir Kumar Rai, Ken Nakatsu, Youping Deng, Mayumi Jijiwa

    Small nucleolar RNAs (snoRNAs) constitute a class of intron-derived non-coding RNAs ranging from 60 to 300 nucleotides. Canonically localized in the nucleolus, snoRNAs play a pivotal role in RNA modifications and pre-ribosomal RNA processing. Based on the types of modifications they involve, such as methylation and pseudouridylation, they are classified into two main families—box C/D and H/ACA snoRNAs. Recent investigations have revealed the unconventional synthesis and biogenesis strategies of snoRNAs, indicating their more profound roles in pathogenesis than previously envisioned. This review consolidates recent discoveries surrounding snoRNAs and provides insights into their mechanistic roles in cancer. It explores the intricate interactions of snoRNAs within signaling pathways and speculates on potential therapeutic solutions emerging from snoRNA research. In addition, it presents recent findings on the long non-coding small nucleolar RNA host gene (lncSNHG), a subset of long non-coding RNAs (lncRNAs), which are the transcripts of parental SNHGs that generate snoRNA. The nucleolus, the functional epicenter of snoRNAs, is also discussed. Through a deconstruction of the pathways driving snoRNA-induced oncogenesis, this review aims to serve as a roadmap to guide future research in the nuanced field of snoRNA–cancer interactions and inspire potential snoRNA-related cancer therapies.


  • Open Access

    Exploring Optimal Biomarker Sources: A Comparative Analysis of Exosomes and Whole Plasma in Fasting and Non-Fasting Conditions for Liquid Biopsy Applications

    by Masaki Nasu, Vedbar S. Khadka, Mayumi Jijiwa, Ken Kobayashi, Youping Deng

    The study of liquid biopsy with plasma samples is being conducted to identify biomarkers for clinical use. Exosomes, containing nucleic acids and metabolites, have emerged as possible sources for biomarkers. To evaluate the effectiveness of exosomes over plasma, we analyzed the small non-coding RNAs (sncRNAs) and metabolites extracted from exosomes in comparison to those directly extracted from whole plasma under both fasting and non-fasting conditions. We found that sncRNA profiles were not affected by fasting in either exosome or plasma samples. Our results showed that exosomal sncRNAs were found to have more consistent profiles. The plasma miRNA profiles contained high concentrations of cell-derived miRNAs that were likely due to hemolysis. We determined that certain metabolites in whole plasma exhibited noteworthy concentration shifts in relation to fasting status, while others did not. Here, we propose that (1) fasting is not required for a liquid biopsy study that involves both sncRNA and metabolomic profiling, as long as metabolites that are not influenced by fasting status are selected, and (2) the utilization of exosomal RNAs promotes robust and consistent findings in plasma samples, mitigating the impact of batch effects derived from hemolysis. These findings advance the optimization of liquid biopsy methodologies for clinical applications.


  • Open Access

    sRNAfrag: A pipeline and suite of tools to analyze fragmentation in small RNA sequencing data

    by Ken M Nakatsu, Mayumi Jijiwa, Vedbar Khadka, Masaki Nasu, Matthew Huo, Youping Deng

    Fragments derived from small RNAs such as small nucleolar RNAs hold biological relevance. However, they remain poorly understood, calling for more comprehensive methods for analysis. We developed sRNAfrag, a standardized workflow and set of scripts to quantify and analyze sRNA fragmentation of any biotype. In a benchmark, it is able to detect loci of mature microRNAs fragmented from precursors and, utilizing multi-mapping events, the conserved 5’ seed sequence of miRNAs which we believe may extraoplate to other small RNA fragments. The tool detected 1411 snoRNA fragment conservation events between 2/4 eukaryotic species, providing the opportunity to explore motifs and fragmentation patterns not only within species, but between. Availability: https://github.com/kenminsoo/sRNAfrag .

  • Open Access

    Circulating microRNA Biomarker for Detecting Breast Cancer in High-Risk Benign Breast Tumors

    by Vedbar S. Khadka, Masaki Nasu, Youping Deng, Mayumi Jijiwa

    High-risk benign breast tumors are known to develop breast cancer at high rates. However, it is still controversial whether they should be removed during diagnosis or followed up until cancer development becomes evident. Therefore, this study sought to identify circulating microRNAs (miRNAs) that could serve as detection markers of cancers arising from high-risk benign tumors. Small RNA-seq was performed using plasma samples collected from patients with early-stage breast cancer (CA) and high-risk (HB), moderate-risk (MB), and no-risk (Be) benign breast tumors. Proteomic profiling of CA and HB plasma was performed to investigate the underlying functions of the identified miRNAs. Our findings revealed that four miRNAs, hsa-mir-128-3p, hsa-mir-421, hsa-mir-130b-5p, and hsa-mir-28-5p, were differentially expressed in CA vs. HB and had diagnostic power to discriminate CA from HB with AUC scores greater than 0.7. Enriched pathways based on the target genes of these miRNAs indicated their association with IGF-1. Furthermore, the Ingenuity Pathway Analysis performed on the proteomic data revealed that the IGF-1 signaling pathway was significantly enriched in CA vs. HB. In conclusion, these findings suggest that these miRNAs could potentially serve as biomarkers for detecting early-stage breast cancer from high-risk benign tumors by monitoring IGF signaling-induced malignant transformation.


  • Open Access

    Machine Learning and Metabolomics: Diagnosis of Malignant Breast Cancer

    by Andrew Winnicki, Yujia Qin, Mayumi Jijiwa, Masaki Nasu, Yuanyuan Fu, Youping Deng

    Breast cancer is one of the leading causes of death among women in the US, and early diagnosis of the disease contributes significantly to the survival rates of patients. Metabolomics data, which can be obtained in a non‐invasive manner through blood plasma sampling, coupled with machine learning methods, has been increasingly applied to the field of biology, opening up a novel dimension of quantitative analysis that has the potential to unlock the secrets to highly complex diseases such as cancer. In this study, machine learning methods were leveraged to analyze several hundred metabolomic signatures of breast cancer patients towards discrimination between malignant and benign tumors. Samples of plasma were taken from 100 female breast cancer patients (50 from malignant and 50 from benign tumors) and metabolite molecules such as lipids and bile acids were extracted using ultra‐performance liquid chromatography coupled with tandem mass spectrometry. The data were then log‐transformed, and metabolites with a significant log‐fold‐change were selected for dimensionality reduction using a Wilcoxon test. These data where then analyzed using an ensemble of 8 different models: decision tree, gradient boosting, random forest, elastic net, linear discriminant analysis, support vector machine, nearest shrunken centroids, and a neural network. The accuracy was evaluated using the ROC cuve and AUC. Variations on these models were included in analysis, including principal component transformations. The most successful model was built using recursive feature selection and a logistic regression model with L1 regularization, which had an accuracy score of 95.0% and a biomarker panel of 42 assembled metabolites from the original 358. With the Wilcoxon‐selected feature set of 62 metabolites, gradient boosting and random forest algorithms also returned accuracy scores of up to 90% and with an AUC of 0.98. Future refinements on these models could eventually lead to the use of the biomarkers in a clinical setting, helping to improve survival rates through early detection of malignant breast cancer tumors.

  • Open Access

    Loss-of-function mutation of c-Ret causes cerebellar hypoplasia in mice with Hirschsprung disease and Down's syndrome

    by Nobutaka Ohgami, Akira Iizuka, Hirokazu Hirai, Ichiro Yajima, Machiko Iida, Atsuyoshi Shimada, Toyonori Tsuzuki, Mayumi Jijiwa, Naoya Asai, Masahide Takahashi, et al.


  • Open Access

    The Function and Mechanism of Lipid Molecules and Their Roles in The Diagnosis and Prognosis of Breast Cancer

    by Rui Guo, Yu Chen, Heather Borgard, Mayumi Jijiwa, Masaki Nasu, Min He, Youping Deng

    Lipids are essential components of cell structure and play important roles in signal transduction between cells and body metabolism. With the continuous development and innovation of lipidomics technology, many studies have shown that the relationship between lipids and cancer is steadily increasing, involving cancer occurrence, proliferation, migration, and apoptosis. Breast cancer has seriously affected the safety and quality of life of human beings worldwide and has become a significant public health problem in modern society, with an especially high incidence among women. Therefore, the issue has inspired scientific researchers to study the link between lipids and breast cancer. This article reviews the research progress of lipidomics, the biological characteristics of lipid molecules, and the relationship between some lipids and cancer drug resistance. Furthermore, this work summarizes the lipid molecules related to breast cancer diagnosis and prognosis, and then it clarifies their impact on the occurrence and development of breast cancer The discussion revolves around the current research hotspot long-chain non-coding RNAs (lncRNAs), summarizes and explains their impact on tumor lipid metabolism, and provides more scientific basis for future cancer research studies.


  • Open Access

    Identification of plasma lipid species as promising diagnostic markers for prostate cancer

    by Xiaoli Chen, Yong Zhu, Mayumi Jijiwa, Masaki Nasu, Junmei Ai, Shengming Dai, Bin Jiang, Jicai Zhang, Gang Huang, Youping Deng

    Background: Prostate cancer is a very common and highly fatal in men. Current non-invasive detection methods like serum biomarker are unsatisfactory. Biomarkers with high accuracy for diagnostic of prostate cancer are urgently needed. Many lipid species have been found related to various cancers. The purpose of our study is to explore the diagnostic value of lipids for prostate cancer. Results: Using triple quadruple liquid chromatography electrospray ionization tandem mass spectrometry, we performed lipidomics profiling of 367 lipids on a total 114 plasma samples from 30 patients with prostate cancer, 38 patients with benign prostatic hyperplasia (BPH), and 46 male healthy controls to evaluate the lipids as potential biomarkers in the diagnosis of prostate cancer. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database was used to construct the potential mechanism pathway. After statistical analysis, five lipids were identified as a panel of potential biomarkers for the detection of prostate cancer between prostate cancer group and the BPH group; the sensitivity, specificity, and area under curve (AUC) of the combination of these five lipids were 73.3, 81.6%, and 0.800, respectively. We also identified another panel of five lipids in distinguishing between prostate cancer group and the control group with predictive values of sensitivity at 76.7%, specificity at 80.4%, and AUC at 0.836, respectively. The glycerophospholipid metabolism pathway of the selected lipids was considered as the target pathway. Conclusions: Our study indicated that the identified plasma lipid biomarkers have potential in the diagnosis of prostate cancer.